For a detailed overview of the platform architecture, immunopeptidomics workflow, quantitative framework, and scientific validation history, please refer to the Valid-NEO® platform introduction page
Services Enabled by Valid-NEO®
Direct Neoantigen Detection and Quantification for Translational Immunotherapy
Valid-NEO® provides direct immunopeptidomics services that experimentally identify and quantify HLA-presented neoantigens from real clinical samples. Rather than relying solely on computational binding prediction, we isolate HLA complexes, identify the peptides actually displayed on the tumor cell surface, and measure their abundance. The result is a validated, quantitatively defined set of targets that can be advanced into therapeutic development with biological certainty.
The platform operates across tumor tissue, biopsies, cell lines, PBMCs, and engineered cells, supporting both HLA Class I and Class II profiling. We confirm mutation-derived neoantigens, shared driver mutation epitopes, and other tumor-specific targets directly from patient material. Output data includes experimentally verified peptide sequences and quantitative surface representation, enabling rational prioritization before resources are committed to TCR engineering, vaccine development, bispecific antibody design, or cell-based therapies.
From Validation to Clinical Integration
Valid-NEO® is structured to integrate seamlessly into translational and clinical development workflows. Identified and quantified epitopes can move directly into therapeutic discovery programs, pharmacodynamic evaluation, and companion biomarker strategies without rebuilding analytical frameworks. The data architecture supports reproducibility, cross-cohort comparison, and structured documentation suitable for clinical trial integration and regulatory engagement.
Workflows are optimized for limited and heterogeneous clinical material, including small biopsies and longitudinal collections. In neoantigen-targeted immunotherapy, the most critical decision is whether a mutation is truly presented at meaningful abundance. Valid-NEO® provides that answer through direct measurement and quantitative validation, allowing development programs to proceed with clarity and confidence.
Major Application Fields
Valid-NEO® supports a broad range of immunotherapy development programs, including:
- Personalized cancer vaccine development
- CAR-T and engineered cell therapy epitope validation
- Shared neoantigen and driver mutation targeting programs
- Companion diagnostic and biomarker strategy development
- TCR discovery and TCR-T cell engineering
- Bispecific antibody and T cell engager development
- Companion diagnostics in clinical trials
- Epitope frequency analysis for population-scale targeting
At vero eos et accusam et justo duo dolores et ea rebum. Stet clita kasd gubergren, no sea takimata sanctus est Lorem ipsum dolor sit amet. Lorem ipsum dolor sit amet, consetetur sadipscing elitr, sed diam nonumy eirmod tempor invidunt ut labore et dolore magna aliquyam erat, sed diam voluptua. At vero eos et accusam et justo duo dolores et ea rebum. Stet clita kasd gubergren, no sea takimata sanctus est Lorem ipsum dolor sit amet. Lorem ipsum dolor sit amet, consetetur sadipscing elitr.